Financial Ratios

CONCORD BIOTECH LTD.

NSE : CONCORDBIOBSE : 543960ISIN CODE : INE338H01029Industry : Pharmaceuticals & DrugsHouse : Private
BSE1559.25-12.7 (-0.81 %)
PREV CLOSE ( ) 1571.95
OPEN PRICE ( ) 1571.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3981
TODAY'S LOW / HIGH ( )1548.75 1595.00
52 WK LOW / HIGH ( )900 1711.95
NSE1559.65-12.15 (-0.77 %)
PREV CLOSE( ) 1571.80
OPEN PRICE ( ) 1574.75
BID PRICE (QTY) 1559.65 (16)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 78790
TODAY'S LOW / HIGH( ) 1547.55 1595.40
52 WK LOW / HIGH ( )900.05 1725
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)29.1322.76187.76247.44177.66
   CEPS(Rs)34.2527.9321.8525.1318.18
   DPS(Rs)8.756.8351.2074.156.00
   Book NAV/Share(Rs)145.80123.501164.131051.11809.71
   Tax Rate(%)25.5325.6025.9524.8520.86
Margin Ratios
   Core EBITDA Margin(%)42.5040.8638.4253.1539.92
   EBIT Margin(%)40.5538.6634.6950.9341.90
   Pre Tax Margin(%)40.2437.5133.8350.7641.67
   PAT Margin (%)29.9727.9125.0538.1532.98
   Cash Profit Margin (%)35.2434.2432.0742.6137.13
Performance Ratios
   ROA(%)18.9615.7812.6819.9318.69
   ROE(%)21.6319.8516.9526.6023.26
   ROCE(%)28.8926.4821.9433.0028.43
   Asset Turnover(x)0.630.570.510.520.57
   Sales/Fixed Asset(x)1.251.131.051.291.73
   Working Capital/Sales(x)1.351.591.481.231.21
Efficiency Ratios
   Fixed Capital/Sales(x)0.800.890.960.770.58
   Receivable days111.87108.22104.87106.80121.87
   Inventory Days75.4287.1589.2778.3472.29
   Payable days149.88179.16144.10192.42146.60
Valuation Parameters
   PER(x)52.250.000.000.000.00
   PCE(x)44.430.000.000.000.00
   Price/Book(x)10.440.000.000.000.00
   Yield(%)0.57
   EV/Net Sales(x)15.620.00-0.030.060.11
   EV/Core EBITDA(x)34.080.00-0.060.100.23
   EV/EBIT(x)38.51-0.01-0.080.110.26
   EV/CE(x)10.370.00-0.010.030.05
   M Cap / Sales15.660.000.000.000.00
Growth Ratio
   Net Sales Growth(%)19.2019.6715.5620.4217.50
   Core EBITDA Growth(%)21.3829.11-12.9944.8619.04
   EBIT Growth(%)25.0233.39-21.3046.3820.02
   PAT Growth(%)27.9733.35-24.1239.2842.72
   EPS Growth(%)27.97-87.88-24.1239.2842.72
Financial Stability Ratios
   Total Debt/Equity(x)0.000.020.050.090.06
   Current Ratio(x)6.303.824.175.742.90
   Quick Ratio(x)4.842.702.884.292.40
   Interest Cover(x)129.5233.6540.31300.20183.92
   Total Debt/Mcap(x)0.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.